Heartseed株式会社 Logo

Heartseed株式会社

Develops iPSC-derived cell therapies to regenerate heart tissue for heart failure.

219A | T

Overview

Corporate Details

ISIN(s):
N/A
LEI:
Country:
Japan
Address:
港区芝浦1丁目2番3号シーバンスS館5階
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Heartseed Inc. is a clinical-stage biotechnology company specializing in regenerative medicine for cardiac diseases. Founded in 2015 as a spin-off from Keio University, the company develops iPSC-derived cell therapies for severe heart failure. Its core strategy is "remuscularization," a novel approach to regenerate damaged heart tissue by transplanting highly purified cardiomyocyte spheroids. The lead pipeline product, HS-001, is an allogeneic iPSC-derived cardiomyocyte therapy administered via intramyocardial injection for patients with heart failure with reduced ejection fraction (HFrEF). Heartseed aims to provide a fundamental treatment for conditions where heart transplantation was previously the only curative option. The company also conducts research on next-generation therapies using autologous and HLA-edited iPSCs to minimize immune rejection.

This is a Fraction of the Available Data.

You're viewing a limited, static snapshot. Professionals use our API to get real-time, AI-ready data for Heartseed株式会社 and 9,000+ other companies.

Stop analyzing yesterday's news. Start building a real-time advantage.

Request Enterprise API Access

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Date Filing Language Size Actions
2025-06-19 09:00
Regulatory News Service
臨時報告書
Japanese 19.9 KB
2025-06-12 08:30
Report Publication Announcement
確認書
Japanese 8.0 KB
2025-06-12 08:30
Interim Report
半期報告書-第10期(2024/11/01-2025/12/31)
Japanese 143.9 KB
2025-01-27 02:01
Regulatory News Service
臨時報告書
Japanese 21.3 KB
2025-01-27 02:01
Regulatory News Service
確認書
Japanese 8.0 KB
2025-01-27 02:00
Annual Report
有価証券報告書-第9期(2023/11/01-2024/10/31)
Japanese 6.0 MB
2025-01-27 02:00
Regulatory News Service
内部統制報告書-第9期(2023/11/01-2024/10/31)
Japanese 21.1 KB
2024-07-22 08:18
Regulatory News Service
訂正有価証券届出書(新規公開時)
Japanese 4.6 MB
2024-07-11 08:00
Regulatory News Service
訂正有価証券届出書(新規公開時)
Japanese 4.6 MB
2024-06-26 08:00
Prospectus
有価証券届出書(新規公開時)
Japanese 9.0 MB

Automate Your Workflow. Get a real-time feed of all Heartseed株式会社 filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

No Financial Data Available

Standardized financial statements for the selected period are not yet available.

Need More History? Access decades of standardized financials for Heartseed株式会社 via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Company Country Ticker View
VENTURE LIFE GROUP PLC Logo
Develops, manufactures, and distributes consumer self-care products and medical devices globally.
United Kingdom VLG
Vetoquinol SA Logo
Develops and markets veterinary drugs and products for companion animals and livestock worldwide.
France VETO
Vifor Pharma AG Logo
A global leader in specialty pharmaceuticals for iron deficiency and nephrology.
Switzerland VIFN
ViGenCell Inc. Logo
Developing T-cell immune therapies to treat cancer and other incurable diseases.
South Korea 308080
Virbac Logo
Develops animal health pharma, vaccines & diagnostics for vets, farmers & pet owners globally.
France FR000
ViroGates A/S Logo
Develops suPAR diagnostic tests for inflammation risk assessment in acute care and longevity.
Denmark VIRO
Vistin Pharma Logo
A leading global producer of Metformin Hydrochloride for the global healthcare market.
Norway VISTN
Vita 34 AG Logo
A cell bank storing umbilical cord stem cells as biological insurance for families' future health.
Germany V3V
Vivoryon Therapeutics N.V. Logo
Developing first-in-class small molecule therapies for age-related and kidney diseases.
Germany VVY
Develops innovative, non-narcotic drugs for pain and central nervous system (CNS) diseases.
South Korea 082800

Talk to a Data Expert

Have a question? We'll get back to you promptly.